Targeting sodium channels in cardiac arrhythmia

被引:27
作者
Remme, Carol Ann [1 ]
Wilde, Arthur A. M. [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Clin & Expt Cardiol, NL-1012 WX Amsterdam, Netherlands
关键词
LONG-QT SYNDROME; MYOCARDIAL-INFARCTION; VENTRICULAR-ARRHYTHMIAS; ATRIAL-FIBRILLATION; HEART-FAILURE; RANOLAZINE; MORTALITY; PATHOPHYSIOLOGY; HETEROGENEITY; (DYS)FUNCTION;
D O I
10.1016/j.coph.2013.11.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cardiac voltage-gated sodium channels are responsible for proper electrical conduction in the heart. During acquired pathological conditions and inherited sodium channelopathies, altered sodium channel function causes conduction disturbances and ventricular arrhythmias. Although the clinical, genetic and biophysical characteristics of cardiac sodium channel disease have been extensively studied, limited progress has been made in the development of treatment strategies targeting sodium channels. Classical non-selective sodium channel blockers have only limited clinical applicability, while more selective inhibitors of the late sodium current constitute a more promising treatment option. Because of our insufficient understanding of their complexity and subcellular diversity, other specific therapeutic targets for modulating sodium channels remain elusive. The current status and future potential of targeting sodium channels in cardiac arrhythmias are discussed.
引用
收藏
页码:53 / 60
页数:8
相关论文
共 54 条
  • [1] Cardiac sodium channel Nav1.5 and interacting proteins: Physiology and pathophysiology
    Abriel, Hugues
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2010, 48 (01) : 2 - 11
  • [2] Electrophysiologic basis for the antiarrhythmic actions of ranolazine
    Antzelevitch, Charles
    Burashnikov, Alexander
    Sicouri, Serge
    Belardinelli, Luiz
    [J]. HEART RHYTHM, 2011, 8 (08) : 1281 - 1290
  • [3] Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure
    Bardy, GH
    Lee, KL
    Mark, DB
    Poole, JE
    Packer, DL
    Boineau, R
    Domanski, M
    Troutman, C
    Anderson, J
    Johnson, G
    McNulty, SE
    Clapp-Channing, N
    Davidson-Ray, LD
    Fraulo, ES
    Fishbein, DP
    Luceri, RM
    Ip, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) : 225 - 237
  • [4] Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine
    Belardinelli, L.
    Shryock, J. C.
    Fraser, H.
    [J]. HEART, 2006, 92 : 6 - 14
  • [5] A Novel, Potent, and Selective Inhibitor of Cardiac Late Sodium Current Suppresses Experimental Arrhythmias
    Belardinelli, Luiz
    Liu, Gongxin
    Smith-Maxwell, Cathy
    Wang, Wei-Qun
    El-Bizri, Nesrine
    Hirakawa, Ryoko
    Karpinski, Serge
    Li, Cindy Hong
    Hu, Lufei
    Li, Xiao-Jun
    Crumb, William
    Wu, Lin
    Koltun, Dmitry
    Zablocki, Jeff
    Yao, Lina
    Dhalla, Arvinder K.
    Rajamani, Sridharan
    Shryock, John C.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 344 (01) : 23 - 32
  • [6] Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death
    Bezzina, Connie R.
    Barc, Julien
    Mizusawa, Yuka
    Remme, Carol Ann
    Gourraud, Jean-Baptiste
    Simonet, Floriane
    Verkerk, Arie O.
    Schwartz, Peter J.
    Crotti, Lia
    Dagradi, Federica
    Guicheney, Pascale
    Fressart, Veronique
    Leenhardt, Antoine
    Antzelevitch, Charles
    Bartkowiak, Susan
    Schulze-Bahr, Eric
    Zumhagen, Sven
    Behr, Elijah R.
    Bastiaenen, Rachel
    Tfelt-Hansen, Jacob
    Olesen, Morten Salling
    Kaeaeb, Stefan
    Beckmann, Britt M.
    Weeke, Peter
    Watanabe, Hiroshi
    Endo, Naoto
    Minamino, Tohru
    Horie, Minoru
    Ohno, Seiko
    Hasegawa, Kanae
    Makita, Naomasa
    Nogami, Akihiko
    Shimizu, Wataru
    Aiba, Takeshi
    Froguel, Philippe
    Balkau, Beverley
    Lantieri, Olivier
    Torchio, Margherita
    Wiese, Cornelia
    Weber, David
    Wolswinkel, Rianne
    Coronel, Ruben
    Boukens, Bas J.
    Bezieau, Stephane
    Charpentier, Eric
    Chatel, Stephanie
    Despres, Aurore
    Gros, Francoise
    Kyndt, Florence
    Lecointe, Simon
    [J]. NATURE GENETICS, 2013, 45 (09) : 1044 - +
  • [7] Ranolazine Reduces Ventricular Tachycardia Burden and ICD Shocks in Patients with Drug-Refractory ICD Shocks
    Bunch, T. Jared
    Mahapatra, Srijoy
    Murdock, David
    Molden, Jamie
    Weiss, J. Peter
    May, Heidi T.
    Bair, Tami L.
    Mader, Katy M.
    Crandall, Brian G.
    Day, John D.
    Osborn, Jeffrey S.
    Muhlestein, Joseph B.
    Lappe, Donald L.
    Anderson, Jeffrey L.
    [J]. PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2011, 34 (12): : 1600 - 1606
  • [8] Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation - Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine
    Burashnikov, Alexander
    Di Diego, Jose M.
    Zygmunt, Andrew C.
    Belardinelli, Luiz
    Antzelevitch, Charles
    [J]. CIRCULATION, 2007, 116 (13) : 1449 - 1457
  • [9] Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation
    Clements-Jewery, H
    Hearse, DJ
    Curtis, MJ
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2005, 145 (05) : 551 - 564
  • [10] MORTALITY AND MORBIDITY IN PATIENTS RECEIVING ENCAINIDE, FLECAINIDE, OR PLACEBO - THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL
    ECHT, DS
    LIEBSON, PR
    MITCHELL, LB
    PETERS, RW
    OBIASMANNO, D
    BARKER, AH
    ARENSBERG, D
    BAKER, A
    FRIEDMAN, L
    GREENE, HL
    HUTHER, ML
    RICHARDSON, DW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (12) : 781 - 788